33P - Establishment of personalized therapeutic for salivary gland cancers based on patients-derived salivary tumoroid model

Background

Three-dimensional (3D) cultures use the property of some cells to self-organize in generate structures that can be programmed to represent an organ or a pathology. The ductal compartment in salivary gland has been identified as the location harboring stem cells.Salivary glands has been investigated using in vivo or ex vivo rudiment culture models. The specific requirements of the niche remain unclear for many cell types, including the pro-acinar cells that give rise to secretory acinar epithelial cells that produce saliva. Organoid cultures are the 3D cultivation of source tissue in a support matrix and specialized media that nearly resembles the physiological environment. Tumor organoids are 3D cultures of cancer cells that can be derived on an individual patient basis with a high success rate. This creates opportunities to build large biobanks with relevant patient material that can be used to perform drug screens and facilitate drug development. In this study, we highlight what is currently known about tumor organoid culture, the advantages of the model system, biobanks of patient-derived tumor organoids are used in drug development research.

Methods

Human salivary gland stem cells (SGSCs) were cultured in 3D tissue cultures with Wnt3a-containing medium. SGSCs were aggregated and formed into 3D spheroid structure in tissue culture plastic (TCP). The SGSC spheroids assembled in 3D tissue culture expressed the significantly higher SGSC and pleuripotency related gene and protein levels.

Results

As a result, we established a tumor organoid model using a three-dimensional (3D) salivary gland organoid culture system. In addition, organoid biobanking was established for patient-specific treatment through analysis and development of various types of tumors.

Conclusions

In conclusion, Tumor organoids are 3D cultures of cancer cells that can be derived on an individual patient basis with a high success rate. This creates opportunities to build large biobanks with relevant patient material that can be used to perform drug screens and facilitate drug development. In addition, it will make a great contribution to the development of patient-specific treatments through biobanking.

Clinical trial identification

Editorial acknowledgement

This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (No. 2019R1C1C1006223).

Legal entity responsible for the study

Chung-Ang University.

Funding

Ministry of Science and ICT (The National Research Foundation of Korea). This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (No. 2019R1C1C1006223).

Disclosure

The author has declared no conflicts of interest.